Regeneron Reports Updated Data From Two Phase 2 Expansion Dose Cohorts Evaluating Investigational Linvoseltamab
(Formerly REGN5458) In Patients With Heavily Pre-Treated, Relapsed/Refractory Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
Regeneron reports updated data from two Phase 2 expansion dose cohorts evaluating investigational linvoseltamab (formerly REGN5458) in patients with heavily pre-treated, relapsed/refractory multiple myeloma. The treatment demonstrated impressive efficacy at the recommended 200 mg dose in the LINKER-MM1 trial.
May 25, 2023 | 9:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron's investigational linvoseltamab demonstrated impressive efficacy in Phase 2 trials for patients with heavily pre-treated, relapsed/refractory multiple myeloma.
The positive results from the Phase 2 trials of linvoseltamab indicate that the treatment is effective in heavily pre-treated, relapsed/refractory multiple myeloma patients. This could potentially lead to increased demand for the treatment and boost Regeneron's revenues, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100